Extending treatment duration in patients with DME whose disease is responsive to steroid therapy could be instrumental in ensuring that visual disruption is kept at a minimum. How might the 3-year results from the PALADIN study guide treatment in the near future? Michael Singer, MD, reviewed data from a phase 4, 3-year, real-world study of patients whose DME was managed with fluocinolone acetonide 0.19 mg implant (Iluvien, Alimera Sciences). And NRR sat down with R.V. Paul Chan, MD, MSc, MBA, who summarized updates to ROP therapy as outlined in the 3rd edition of the International Classification of Retinopathy of Prematurity. What are the updates, and what spurred the ICROP to make them? Tune in to find out. 

This editorially independent podcast is supported with advertising.